Order comes before the molecule
A peer-reviewed Nature Microbiology paper tied clonal expansion of monophasic Salmonella Typhimurium ST34 to sequential gene loss across 44,597 genomes. Figure captions show ST34 outperforming previously prevalent ST19, and a dinB frameshift predominantly in that lineage. That is a genomic and laboratory mechanism, not a new medicine.[1]
The abstract says a frameshift in dinB, a polymerase for translesion DNA synthesis, changes flagellin expression, after which loss of flagellin gene fljB alters requirements for gut infection. In-vivo competition and Figure 4 present fliC retention with fljB loss as a competitive advantage. Figure 5 states the order: dinB then fljB. Temporal evolutionary modelling supports that sequence in ST34 expansion.[1]
For patients the sequence is not a prescription
A zoonotic lineage pulling ahead in gut competition is not a new pill in clinic. The evidence convinces me ST34 is marked by an ordered loss that changes infection requirements, not by a worse toxin. In-vivo competition is a gut model, not a human trial. There is no treatment recommendation here.[1]
The authors offer the mechanism as insight relevant to forecasting future pandemics. The concrete signal I would watch is whether the same dinB-then-fljB order reappears in independent genome collections outside ST34. If it does not, the account stays lineage-specific, and pandemic-forecast language would overreach.[1]